Video

Dr. Hamid on Epacadostat Plus Pembrolizumab in Advanced Melanoma

Author(s):

Omid Hamid, MD, director of the melanoma center at the Angeles Clinic & Research Institute in Los Angeles, discusses the phase III results of the ECHO-202/KEYNOTE-037 trial, which explored the IDO inhibitor epacadostat plus pembrolizumab (Keytruda) in patients with advanced melanoma.

Omid Hamid, MD, director of the melanoma center at the Angeles Clinic & Research Institute in Los Angeles, discusses the phase I/II results of the ECHO-202/KEYNOTE-037 trial, which explored the IDO inhibitor epacadostat plus pembrolizumab (Keytruda) in patients with advanced melanoma.

This was consistent with the initial results of the phase I trial, which demonstrated an overall response rate at around 55%, a disease control rate of about 70%, and an 18-month progression-free survival rate at more than 50%. Additionally, this was a very tolerable regimen that was not associated with significant toxicities.

This is important because prior combination therapies have shown similarly high response rates, but are linked with significant grade 3/4 toxicities—usually at 50%. Whereas, this combination showed grade 3/4 events at around 20% and a less than 10% grade 3/4 immune-related toxicities. This is a regimen that, if it shows benefit, then it is very translatable into the community, Hamid says. The phase III trial is currently ongoing, he concludes.

<<< View more from the 2017 ESMO Congress

Related Videos
Thach-Giao Truong, MD, medical director, Melanoma Program, Cleveland Clinic
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Ashraf Z. Badros, MBCHB
Alexander C. Van Akkooi, MD, PhD, FRACS
Meredith McKean, MD
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School